Our findings are in agreement with previous studies that reported that VPAC1 facilitates productive HIV-1 infection in CD4+ tumor cell lines [27], and that VPAC2 activation inhibits HIV-1 integration and viral production in CD4+ tumor cell lines and PBMCs [28]. Here, VIPR2 is linked to neoplasm.